Table 4 Efficacy of AC in different subgroups
| Â | 1,2,5-y OS | 1,2,5-y LFFS | 1,2,5-y DFFS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
CRT-alone | CRT-AC | p | CRT-alone | CRT-AC | p | CRT-alone | CRT-AC | p | ||
Clinical N stage | N0 | 76.5, 58.8, 52.3 | 95.0, 81.0, 66.7 | 0.297 | 69.3, 69.3, 69.3 | 95.2, 95.2, 89.6 | 0.105 | 94.4, 87.2, 87.2 | 95.2, 89.6, 89.6 | 0.777 |
N1 | 68.2, 37.9, 23.5 | 79.0, 33.6, 14.4 | 0.324 | 69.7, 58.8, 55.3 | 62.6, 45.7, 31.3 | 0.131 | 68.9, 60.7, 57.3 | 78.5, 68.3, 53.4 | 0.377 | |
N2 | 40.0, 26.7, 0.0 | 33.0, 0.0, 0.0 | 0.785 | 51.9, 0.0, .0.0 | 33.3, 33.3, 33.3 | 0.877 | 80.0, 53.3, 53.3 | 0.0, 0.0, 0.0 | 0.942 | |
Clinical M stage | M0 | 71.7, 45.8, 35.5 | 79.7,57.0, 31.0 | 0.880 | 70.0, 61.0, 61.0 | 70.6, 63.5, 57.1 | 0.860 | 79.5, 70.3, 67.5 | 89.6, 79.4, 79.4 | 0.191 |
M1 | 50.0, 18.2, 4.5 | 50.0, 18.7, 12.5 | 0.936 | 60.6, 44.2, 29.5 | 67.3, 26.9, 0.0 | 0.692 | 52.6, 46.1, 46.1 | 59.2, 47.4, 47.4 | 0.792 | |
Clinical TNM stage | II | 75.3, 43.9,43.9 | 95.0, 80.0, 55.0 | 0.208 | 72.7, 58.2, 58.2 | 90.0, 90.0, 84.4 | 0.079 | 81.6, 74.2, 74.2 | 95.0, 95.0, 87.1 | 0.195 |
III | 71.7, 37.9, 33.2 | 61.1, 38.9, 16.7 | 0.378 | 68.8, 51.6, 51.6 | 59.3, 37.6, 37.6 | 0.549 | 61.4, 62.2, 62.2 | 87.7, 68.2, 56.8 | 0.598 | |
IVA | 69.7, 54.9, 33.8 | 67.7, 38.7, 23.5 | 0.651 | 77.8, 72.9, 72.9 | 64.2, 59.9, 47.2 | 0.120 | 86.7, 76.6, 69.7 | 86.6, 71.9, 63.9 | 0.878 | |
short-term response | CR | 88.5,76.5,58.4 | 100, 87.5,78.0 | 0.274 | 88.0, 79.4, 74.1 | 95.8, 91.3, 84.2 | 0.276 | 84.4, 76.2, 71.1 | 95.8, 83.3, 74.8 | 0.590 |
PR | 46.1,17.1,12 | 60.0, 20.0, 0.0 | 0.998 | 55.4, 50.8, 50.8 | 68.2, 52.8, 33.0 | 0.954 | 60.6, 48.6, 48.6 | 67.9, 55.7, 55.7 | 0.470 | |
SD | 77.4, 36.1,24 | 56.3, 37.2, 22.3 | 0.616 | 65.7, 48.3, 48.3 | 50.8, 36.9, 31.6 | 0.277 | 80.3, 72.3, 72.3 | 92.8, 86.2, 77.6 | 0.117 | |
PD | 25.0, 0.0, 0.0 | 33.3, 0.0, 0.0 | 0.704 | 33.3, 33.3, 33.3 | 66.7, 66.7, 66.7 | 0.642 | 75.0, 75.0, 75.0 | 0.0, 0.0, 0.0 | 0.247 | |